ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease
Authors' conclusion
Lipid-related atherosclerotic risk is most accurately reflected by the total count of apoB-P and is largely unaffected by the major particle type (VLDL, LDL) or size. Elevated count of Lp(a) adds additional risk
Study context
- Population
- UK Biobank participants with lipoprotein profiling, without prior atherosclerotic disease, diabetes or lipid-lowering therapy
- Participants
- 207,368 participants
- Exposure
- ApoB particle count, type and size vs incident coronary artery disease (CAD)
- Outcome
- Incident CAD
Methodological detailsUK Biobank, multivariable-adjusted Cox regression
- UK Biobank
- Multivariable-adjusted Cox regression
Main finding
As reported in the abstract
Hazard ratio (95% CI)
apoB-Pper 1-SD increase
1.33(1.30–1.36)
VLDL particlesper 100 nmol/L
1.22(1.11–1.34)
LDLper 100 nmol/L
1.07(1.05–1.08)
Each row per its own increment, as printed
Observational data: associations, not effects.
Further findings
Lp(a) (immunoassay), adjusted for apoB particle (apoB-P)
| HR (CI) | ||
|---|---|---|
| Lp(a)After apoB-P adjustment | 1.18 (1.16–1.20) | |
| 0.512Hazard ratio (log scale) |
- Lp(a) (immunoassay), adjusted for apoB-P — Lp(a) added independent prognostic value for CAD: AUC 0.769 vs 0.774
- P < .001
Particle diameter or size subclasses
- Not associated with CAD after apoB-P adjustment
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. Eur Heart J. Published 28 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →